ASH 2017: CAR-T Wallops Blood Cancer
The American Society of Hematology (ASH) annual meeting this past weekend was chock-full of excitement, including an unexpected snowstorm in Atlanta and a slew of game-changing non-Hodgkin lymphoma (NHL) and multiple myeloma trial results for chimeric antigen receptor T-cell therapies (CAR-T). These CAR-T trial results suggest we're fast approaching a major shift in how we battle blood cancer, so let's look at the latest data.
Cancer cells often express proteins on their surface that healthy cells usually don't, and CAR-T therapy that targets those proteins is proving to be an effective way to battle back against blood cancer.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Bluebird Bio Inc. Stock
€0.95
0.420%
Currently there is a rather negative sentiment for Bluebird Bio Inc. with 4 Buy predictions and 6 Sell predictions..
However, we have a potential of 533.04% for Bluebird Bio Inc. as the target price of 6 € is above the current price of 0.95 €.
